1 Wall Street Analyst Thinks Abbvie Stock Is Going To $200. Is It A Buy At Around $165?
Wall Street is feeling pretty good about AbbVie's (NYSE: ABBV) performance in 2024 so far.
Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen also slapped a $200 price target on the pharma stock, which implies a gain of more than 20% from recent prices.
The positive rating is more than a little surprising because AbbVie's lead drug, Humira, lost its market exclusivity in the U.S. last year.
Why AbbVie's a buy despite Humira's patent cliff
Instead of a sharp sales contraction in the first quarter, AbbVie's revenue rose 0.7% year over year. On the bottom line, the company earnings shrank by just 6.1% to an adjusted $2.31 per share.
U.S. sales of Humira plummeted by 39.9% year over year in the first quarter to $1.8 billion. Luckily, sales of Rinvoq, an arthritis tablet, and Skyrizi, a psoriasis injection, offset the loss. Skyrizi sales soared 47.6% to $2.0 billion and Rinvoq sales jumped 59.3% to $1.1 billion.
A planned acquisition of Cerevel Therapeutics for around $8.7 billion in cash could add a potential new blockbuster to AbbVie's late-stage development pipeline. The next-generation antipsychotic candidate, called emraclidine, appears to get the job done for people with schizophrenia with fewer side effects than currently available treatments.
In the numbers
At recent prices, you can scoop up shares of AbbVie for about 14.8 times the midpoint of management's guidance range for 2024 adjusted earnings. That's a very reasonable valuation for a business that could begin raising its earnings again at a high single-digit percentage in 2025. Plus, the stock pays a nice dividend that currently yields 3.7% -- money that you get to keep even if things don't work out as expected. Adding some AbbVie shares to a diversified portfolio looks like it would be a wise move for most investors.
Should you invest $1,000 in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $566,624!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of May 13, 2024
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends AbbVie. The Motley Fool has a disclosure policy.
